Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS

Corvus Pharmaceuticals — ASCO 2017

17 slides from Corvus Pharmaceuticals's conference presentation, June 2017

  1. Slide 1: Safety and clinical activity of CPI-444 in anti-PD1/PDL1 refractory RCC and NSCLC

    Abstract #: 3004 Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients Presenter: Lawrence Fong, M.D. Leader, Cancer Immunotherapy Program Co-Director, Parker Institute

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Forward Looking Statements This presentation contains forward-looking statements, including statements related to the potential safety and efficacy of CPI-444, both as a single agent and in combination with anti-PD-1 and anti-PD-L1, and the Company’s ability to develop and

  3. Slide 3: Safety and clinical activity of A2aR antagonist CPI-444 in RCC and NSCLC patients

    Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444 in anti-PD(L)1 treatment- refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients Lawrence Fong, Patrick Forde, John Powderly II, Jonathan Goldman, John Nemunaitis, Jason Luke, Matthew Hellmann, Shi

  4. Slide 4: Background

    Background • Anti-PD-(L)1 antibodies are approved for treatment of RCC and NSCLC but a small proportion of patients benefit. • No approved agents overcome resistance to anti-PD-(L)1 with few reporting benefit in PD-1 resistant/ refractory setting. • Converting tumors devoid of T cell infiltration (“

  5. Slide 5: Adenosine Suppresses Immunity and is a Potential Mechanism of Resistance to PD-(L)1 Therapy

    Adenosine Suppresses Immunity and is a Potential Mechanism of Resistance to PD-(L)1 Therapy Adenosine in the tumor microenvironment CD73 expression in baseline tumor biopsies from the CPI-444 phase 1 trial T Cell Adenosine p=0.001 10,000 T cell inhibition CD73 Expression (mRNA) AMP ATP CD73 CD39 A2A

  6. Slide 6: Phase 1/1b Clinical Study with Oral Drug CPI-444

    Phase 1/1b Clinical Study with Oral Drug CPI-444 Expansion cohorts: renal cell and non-small cell lung cancer Dose Selection Cohort Expansion CPI-444 Monotherapy 100 mg BID or 200 mg QD, 100 mg BID 28 days 14 or 28 days CPI-444 Dose Selection Cohort Expansion with atezolizumab 50 mg BID or 100 mg BI

  7. Slide 7: CPI-444 Blocks A2A Receptor Signaling

    CPI-444 Blocks A2A Receptor Signaling 150 CD4+ T cell A2AR (% Relative to Baseline) A2AR Pathway Activity Adenosine cAMP pCREB 100 CPI-444 CPI-444 50 Analysis of pCREB by flow 0 0 5000 10000 15000 cytometry Adenosine (NECA) Plasma CPI-444 CPI-444 (ng/ml) (ng/mL) stimulation ex vivo 50mg BID 100mg BI

  8. Slide 8: Patient Characteristics

    Patient Characteristics Non-Small Cell Lung Cancer Renal Cell Cancer (N=45) (N=30) Prior anti-PD-(L)1 exposure Naïve 8 (18%) 8 (27%) Resistant/Refractory 37 (82%) 22 (73%) PD-L1 Negative* 54% 95% Median time since IO agent, months (range) 2.8 (0.6 – 24) 1.7 (1 – 71) Histology 28 (62%) Non squamous 2

  9. Slide 9: Treatment-Related Adverse Events

    Treatment-Related Adverse Events Adverse Events (Gr1/2) > 5% Frequency (n=75) Single Agent (%) Combination (%) Fatigue 11 15 Grade > 3 AEs: • Single agent: none Nausea 6 8 Pruritus 8 5 • Combination CPI-444 + atezolizumab Constipation 6 --- • One patient with Gr 3 immune related hepatitis, pneumonit

  10. Slide 10: Phase 1/1b Trial with CPI-444: Disease Control in NSCLC

    Phase 1/1b Trial with CPI-444: Disease Control in NSCLC Partial responses can be seen in anti-PD-1 progressors CPI-444 Disease Control Duration Combination (CPI-444+atezolizumab) (%) Change from Baseline Patients -+ - -+- - - +++ - + - + +- Resistant/refractory to prior IO Naïve to prior IO Treatmen

  11. Slide 11: Phase 1/1b Trial with CPI-444: Disease Control in Renal Cell Cancer

    Phase 1/1b Trial with CPI-444: Disease Control in Renal Cell Cancer Partial responses can be seen in an anti-PD-1 progressing and naïve patients CPI-444 Disease Control Duration Combination (CPI-444+atezolizumab) (%) Change from Baseline Patients - - - - - - - - - - - - - - Resistant/refractory to p

  12. Slide 12: Tumor Growth Kinetics in "Stable" RCC Patients

    Tumor Growth Kinetics in “Stable” RCC Patients CPI-444 Single Agent CPI-444 in Combination with Atezolizumab 103101 SLD Nivolumab Anti-PD-1 Naïve Anti-PD-1 Naïve 103210Refractory SLD 20 20 Relative Target Lesion(s) Size 20 Relative Target Lesion(s) Size Prior to CPI-444 On CPI-444 Percent Change in

  13. Slide 13: Tumor Regression in Nivolumab Refractory Renal Cancer

    Tumor Regression in Nivolumab Refractory Renal Cancer Single Agent CPI-444 Five prior regimens including TKIs, mTOR inhibitor, and nivolumab Pre-treatment Post Dose (8w) H&E 14% >70% CD8 IHC Pre-treatment 3 months of treatment Ph I CPI-4441311 Trial 13

  14. Slide 14: CPI-444 Induces CD8 T Cell Infiltration and Th1 Gene Expression in Tumor Tissues

    CPI-444 Induces CD8 T Cell Infiltration and Th1 Gene Expression in Tumor Tissues CD8 T Cell Change (IHC) Immune Gene Expression (paired biopsies) 5 NSCLC CXCL10 4 GZMB 10 SD CD8 Ratio (Post/Pre biopsy) PD-L1 3 Pre-dose Post-dose -log P value CXCL16 CXCL11 OPG 1 PR RCC TEFF_SIG GZMA CCL17 2 PD-L2 ICA

  15. Slide 15: CPI-444 Expands New T Cell Clones in Blood and Tumor

    CPI-444 Expands New T Cell Clones in Blood and Tumor Blood Tumor Biopsy 10 • RCC patient with PR on single-agent CPI-444 Post treatment Posttreatment dose Biopsy • T cell receptor (TCR) 1 sequencing of blood and tumor biopsies pre- and post-treatment Post 0.1 • T cell clonotypes can be matched betwe

  16. Slide 16: Phase 1/1b Trial with CPI-444: Summary

    Phase 1/1b Trial with CPI-444: Summary • CPI-444 is well-tolerated as a monotherapy and in combination with atezolizumab • CPI-444 has clinical activity alone and in combination with atezolizumab • Anti-tumor activity seen in: – Patients who have progressed on prior anti-PD-(L)1 – Patients with PD-L

  17. Slide 17: Acknowledgements

    Acknowledgements • The patients and their families • Participating Centers: British Columbia Cancer Agency, Carolina BioOncology Institute, Cleveland Clinic, Columbia University Medical Center, Cross Cancer Institute, Emory University, Georgetown University, Indiana University, Johns Hopkins Univers

Corvus Pharmaceuticals — ASCO 2017 on 6ix